Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma (NGF-Glaucoma)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02855450
Recruitment Status : Completed
First Posted : August 4, 2016
Last Update Posted : June 25, 2019
Sponsor:
Collaborator:
Cromsource
Information provided by (Responsible Party):
Dompé Farmaceutici S.p.A

Brief Summary:

The primary objective of the study is to assess the safety and tolerability of a 180μg/ml TID dose regimen of recombinant human nerve growth factor (rhNGF) eye drop solution administered over 8 weeks versus a vehicle control in patients with progressive primary open-angle glaucoma despite IOP control.

The secondary objectives are to measure the changes in BCDVA, visual field, ERG and structural changes in ganglion cell layer and nerve fiber layer thickness measured by optical coherence tomography. The secondary outcomes will be examined at 1, 4 and 8 weeks of therapy, and at 4 and 24 weeks after cessation of therapy (Week 12 visit and Week 32 visit), and will include functional assessments to investigate evidence of a persistent biological effect after discontinuation of the study treatment.


Condition or disease Intervention/treatment Phase
Glaucoma Drug: rhNGF Drug: Vehicle Phase 1

Detailed Description:

This is an 8 Week phase Ib, monocentric, randomized, double-masked, vehicle controlled, parallel groups, study with a 24 Week follow-up period to evaluate the safety and potential efficacy of a 180 μg/ml recombinant human nerve growth factor (rhNGF) eye drops solution versus vehicle in 60 study participants with chronic primary open angle glaucoma.

Participants may qualify with either progressive optic neuropathy despite maximal current therapy (i.e. IOP reduction), or with stabilized IOP but diminished vision (central or peripheral).

Participants with a qualifying eye will be randomized 2:1 to topical recombinant human nerve growth factor (rhNGF) therapy or vehicle placebo control. Examinations for safety and efficacy will occur one week following initiation of therapy, and at 4, 8, 12 and 32 weeks.

All participants in either arm will be followed clinically at 4 weeks after cessation of therapy.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: An 8 Week Phase Ib, Monocentric, Randomized, Double-masked, Parallel Groups, Study With a 24 Week Follow-up to Evaluate Safety and Potential Efficacy of a 180 μg/ml rhNGF Eye Drops Solution Vs Vehicle in Patients With Glaucoma
Actual Study Start Date : December 2016
Actual Primary Completion Date : May 2018
Actual Study Completion Date : May 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Arm Intervention/treatment
Experimental: rhNGF
rhNGF (Recombinant Human Nerve Growth Factor) 180 μg/ml eye drops solution
Drug: rhNGF
Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution three times a day (TID) for 8 weeks of treatment.
Other Name: cenegermin

Placebo Comparator: Vehicle
Ophthalmic Placebo solution
Drug: Vehicle
Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution times a day (TID) for 8 weeks of treatment.
Other Name: placebo




Primary Outcome Measures :
  1. IOP [ Time Frame: Week 8 ]
    IntraOcular Pressure


Secondary Outcome Measures :
  1. IOP [ Time Frame: Screening ]
    IntraOcular Pressure

  2. IOP [ Time Frame: Week 1 ]
    IntraOcular Pressure

  3. IOP [ Time Frame: Week 4 ]
    IntraOcular Pressure

  4. IOP [ Time Frame: Week 12 ]
    IntraOcular Pressure

  5. IOP [ Time Frame: Week 32 ]
    IntraOcular Pressure

  6. BCDVA [ Time Frame: Screening ]
    Best corrected distance visual acuity

  7. BCDVA [ Time Frame: Week 8 ]
    Best corrected distance visual acuity

  8. BCDVA [ Time Frame: Week 32 ]
    Best corrected distance visual acuity

  9. HVF 24-2 or 10-2 [ Time Frame: Screening ]
    Humphrey Visual Field 24-2 or 10-2

  10. HVF 24-2 or 10-2 [ Time Frame: Week 1 ]
    Humphrey Visual Field 24-2 or 10-2

  11. HVF 24-2 or 10-2 [ Time Frame: Week 8 ]
    Humphrey Visual Field 24-2 or 10-2

  12. HVF 24-2 or 10-2 [ Time Frame: Week 32 ]
    Humphrey Visual Field 24-2 or 10-2

  13. Dilated fundus ophthalmoscopy [ Time Frame: Screening ]
    Dilated fundus ophthalmoscopy - Optic Nerve - Choroid - Retina/Macula - Vitreous - Cup/Disc Ratio

  14. Dilated fundus ophthalmoscopy [ Time Frame: Week 1 ]
    Dilated fundus ophthalmoscopy -Optic Nerve - Choroid - Retina/Macula - Vitreous - Cup/Disc Ratio

  15. Dilated fundus ophthalmoscopy [ Time Frame: Week 4 ]
    Dilated fundus ophthalmoscopy -Optic Nerve - Choroid - Retina/Macula - Vitreous - Cup/Disc Ratio

  16. Dilated fundus ophthalmoscopy [ Time Frame: Week 8 ]
    Dilated fundus ophthalmoscopy - Optic Nerve - Choroid - Retina/Macula - Vitreous - Cup/Disc Ratio

  17. Dilated fundus ophthalmoscopy [ Time Frame: Week 32 ]
    Dilated fundus ophthalmoscopy - Optic Nerve - Choroid - Retina/Macula - Vitreous - Cup/Disc Ratio

  18. ERG [ Time Frame: Day 0 ]
    Electroretinogram - Amplitude A1-B1 Photopic 3.0 (0.5 Hz), Latency ISO-B1 Photopic 3.0 (0.5 Hz), Amplitude ISO-B1 Scotopic 0.01 (0.5 Hz), Latency ISO-B1 Scotopic 0.01 (0.5 Hz), Amplitude ISO-B1 Photopic 3.0 Flicker 30 Hz, Latency ISO-B1 Photopic 3.0 Flicker 30 Hz, Amplitude N1-P1 wave oscillatory potential (1 Hz), Latency N1-P1 wave oscillatory potential (1 Hz)

  19. ERG [ Time Frame: Week 8 ]
    Electroretinogram - Amplitude A1-B1 Photopic 3.0 (0.5 Hz), Latency ISO-B1 Photopic 3.0 (0.5 Hz), Amplitude ISO-B1 Scotopic 0.01 (0.5 Hz), Latency ISO-B1 Scotopic 0.01 (0.5 Hz), Amplitude ISO-B1 Photopic 3.0 Flicker 30 Hz, Latency ISO-B1 Photopic 3.0 Flicker 30 Hz, Amplitude N1-P1 wave oscillatory potential (1 Hz), Latency N1-P1 wave oscillatory potential (1 Hz)

  20. ERG [ Time Frame: Week 32 ]
    Electroretinogram - Amplitude A1-B1 Photopic 3.0 (0.5 Hz), Latency ISO-B1 Photopic 3.0 (0.5 Hz), Amplitude ISO-B1 Scotopic 0.01 (0.5 Hz), Latency ISO-B1 Scotopic 0.01 (0.5 Hz), Amplitude ISO-B1 Photopic 3.0 Flicker 30 Hz, Latency ISO-B1 Photopic 3.0 Flicker 30 Hz, Amplitude N1-P1 wave oscillatory potential (1 Hz), Latency N1-P1 wave oscillatory potential (1 Hz)

  21. AE [ Time Frame: Screening ]
    Adverse events

  22. AE [ Time Frame: Day 0 ]
    Adverse events

  23. AE [ Time Frame: Week 1 ]
    Adverse events

  24. AE [ Time Frame: Week 4 ]
    Adverse events

  25. AE [ Time Frame: Week 8 ]
    Adverse events

  26. AE [ Time Frame: Week 12 ]
    Adverse events

  27. AE [ Time Frame: Week 32 ]
    Adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients 18 years of age or older. Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.
  2. Participant's clinical diagnosis must be consistent with glaucoma characterized by the following features: a) clinical evidence of progressive RGC dysfunction and degeneration using visual field and/or a structural modality. There must be at least 3 reliable visual fields within 14 months prior to entering into the study; b) residual visual field preservation in at least 1 quadrant.
  3. Participant must be medically able to undergo the testing required in the flowsheet of exam procedures.
  4. Females of childbearing potential must agree to use an effective form of birth control.

Exclusion Criteria:

  1. Participant has another optic nerve or retinal degenerative disease or co-morbidity causing significant vision loss, irrespective of whether it is currently treated or untreated, that could limit the possibility of visual recovery.
  2. Participant is blind in one eye.
  3. Participant has a requirement of acyclovir and/or related products during study duration. 4- Participant has evidence of corneal opacification or lack of optical clarity.
  4. Participant has evidence of corneal opacification or lack of optical clarity.
  5. Participant has undergone lens removal in the last 3 months, with or without intra-ocular lens implantation, or has undergone intra-ocular lens replacement within 3 months, or has undergone any other ocular surgery within 9 months prior to initiation of study drug.
  6. Participant is receiving systemic steroids or other immunosuppressive medications.
  7. Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a non-clinically approved drug by ocular or systemic administration.
  8. Participant has uveitis or other ocular inflammatory disease.
  9. Participant has diabetic macular edema.
  10. Participant has a history of ocular herpes zoster.
  11. Participant is on chemotherapy.
  12. Participant has a history of malignancy, not counting basal cell carcinomas, UNLESS it was treated successfully 2 years prior to inclusion in the trial.
  13. Known hypersensitivity to one of the components of the study or procedural medications.
  14. History of drug, medication or alcohol abuse or addiction.
  15. Females of childbearing potential (those who are not surgically sterilized or post- menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:

    1. are currently pregnant or,
    2. have a positive result on the urine pregnancy test at the Screening/Baseline Visit or,
    3. intend to become pregnant during the study treatment period or,
    4. are breast-feeding or,
    5. not willing to use highly effective birth control measures, such as: Hormonal contraceptives - oral, implanted, transdermal, or injected and/or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or IUD during the entire course of and 30 days after the study treatment periods.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02855450


Locations
Layout table for location information
United States, California
Byers Eye Institute at Stanford University
Palo Alto, California, United States, 94303
Sponsors and Collaborators
Dompé Farmaceutici S.p.A
Cromsource
Investigators
Layout table for investigator information
Principal Investigator: Jeffrey L Goldberg, MD, PhD , MD, PhD

Layout table for additonal information
Responsible Party: Dompé Farmaceutici S.p.A
ClinicalTrials.gov Identifier: NCT02855450     History of Changes
Other Study ID Numbers: NGF0314
First Posted: August 4, 2016    Key Record Dates
Last Update Posted: June 25, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma
Ocular Hypertension
Eye Diseases
Ophthalmic Solutions
Pharmaceutical Solutions